Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates. The stock has gained 434.64% over the last 5 years ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The results that exceeded Wall Street expectations pushed the U.S. drugmaker's shares up nearly 13% in premarket trading, ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current ... U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a note on Friday said prescriptions ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...